GSK to progress development of ChemoCentryx's Traficet-EN

GlaxoSmithKline and ChemoCentryx today announced that GSK has exercised its option to obtain an exclusive license for further development and worldwide commercialization of Traficet-EN (CCX282-B), a specific CCR9 antagonist that could offer a new approach for treating inflammatory bowel diseases. The option also encompasses two further identified backup compounds and represents the first product licensing opportunity resulting from the original collaboration with ChemoCentryx through GSK's Center of Excellence for External Drug Discovery. Release

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.